• IVF Hartmann posted first-half 2026 revenue up 11.3% to CHF 85.9 million; EBIT rose 27.5% to CHF 12.1 million.
• EBIT margin widened 1.7 percentage points to 14%; net profit climbed 24.7% to CHF 10.3 million.
• Growth was driven by market-share gains and temporary customer stockpiling tied to economic uncertainty; cost and supplier management stayed tight.
• Segment revenue rose 13.9% to CHF 34.3 million in infection management; incontinence management increased 13.8% to CHF 20.6 million.
• For 2026, it expects revenue and EBIT above 2025, while flagging weaker second-half growth as stockpiling effects fade.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IVF Hartmann Holding AG published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.